{"nctId":"NCT02484911","briefTitle":"Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting","startDateStruct":{"date":"2015-05"},"conditions":["Chemotherapy-induced Nausea and Vomiting"],"count":120,"armGroups":[{"label":"Olanzapine regimen","type":"EXPERIMENTAL","interventionNames":["Drug: Olanzapine","Drug: Aprepitant","Drug: Palonosetron","Drug: Dexamethasone"]},{"label":"Control regimen","type":"OTHER","interventionNames":["Drug: Aprepitant","Drug: Palonosetron","Drug: Dexamethasone"]}],"interventions":[{"name":"Olanzapine","otherNames":[]},{"name":"Aprepitant","otherNames":[]},{"name":"Palonosetron","otherNames":[]},{"name":"Dexamethasone","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. 18 years of age or older\n2. Histologically or cytologically confirmed malignant disease\n3. Accept chemotherapy for the first time\n4. Patients who will receive high emetogenic cancer chemotherapy (HEC) (cisplatin\\>=70mg/m2,adriamycin in combination with cyclophosphamide ,cyclophosphamide\\>=1500mg/m2,adriamycin\\>60mg/m2,epirubicin\\>90mg/m2,dacarbazine，ifosfamide\\>=2g/m2) or moderate emetogenic chemotherapy cancer (carboplatin\\>=300mg/m2,cyclophosphamide\\>=600-1000mg/m2,adriamycin\\>50mg/m2)\n5. Written informed consent\n\nExclusion Criteria:\n\n1. Pregnant or breast-feeding\n2. Uncontrolled psychosis history\n3. Inability or unwillingness to understand or cooperate with study procedures\n4. Central nervous system tumors primary or secondary\n5. Concurrent abdominal radiotherapy\n6. History of uncontrolled diabetes mellitus\n7. Patients of prostatic hyperplasia ，paralytic ileus，narrow feet glaucoma.\n8. Known cardiac arrhythmia, uncontrolled congestive heart failure ,or acute myocardial infarction with the previous six month\n9. Pre-existing nausea or vomiting\n10. Inadequate hematological function and abnormal liver and renal function.\n11. History of sensitivity to olanzapine\n12. Concurrent application of quinolone antibiotic therapy\n13. Treatment with another antipsychotic agent such as risperidone,quetiapine, clozapine,phenothiazine,or butyrophenone for 30 days prior to or during the chemotherapy.\n14. Cytochrome P450 3A4 substrates within 7 days (terfenadine, cisapride, astemizole, pimozide)\n15. Concurrent application of systemic corticosteroids\n16. Active infection or gastrointestinal dysfunction","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Participants Receiving HEC With Complete Response in Overall Phase","description":"Overall phase was defined as 0 to 120 hours following initiation of chemotherapy.\n\nComplete response was defined as no vomiting with no rescue therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"PRIMARY","title":"Proportion of Participants Receiving MEC With Complete Response in Overall Phase","description":"Overall phase was defined as 0 to 120 hours following initiation of chemotherapy.\n\nComplete response was defined as no vomiting with no rescue therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Receiving HEC With Complete Response in the Acute Phase","description":"Acute phase was defined as 0 to 24 hours following initiation of chemotherapy. Complete response was defined as no vomiting with no rescue therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Receiving HEC With Complete Response in the Delayed Phase","description":"Delayed phase was defined as 24 to 120 hours following initiation of chemotherapy.\n\nComplete response was defined as no vomiting with no rescue therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Receiving HEC With No Vomiting in the Overall Phase","description":"Overall phase was defined as 0 to 120 hours following initiation of chemotherapy.\n\nNo vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Receiving HEC With No Vomiting in the Acute Phase","description":"Overall Phase was defined as 0 to 120 hours following initiation of chemotherapy.\n\nNo vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue ）","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Receiving HEC With No Vomiting in the Delayed Phase","description":"Overall Phase was defined as 24 to 120 hours following initiation of chemotherapy.\n\nNo vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Receiving MEC With Complete Response in the Acute Phase","description":"Acute phase was defined as 0 to 24 hours following initiation of chemotherapy. Complete response was defined as no vomiting with no rescue therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Receiving MEC With Complete Response in the Delayed Phase","description":"Delayed phase was defined as 24 to 120 hours following initiation of chemotherapy.\n\nComplete response was defined as no vomiting with no rescue therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Receiving MEC With No Vomiting in the Overall Phase","description":"Overall Phase was defined as 0 to 120 hours following initiation of chemotherapy.\n\nNo vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Receiving MEC With No Vomiting in the Acute Phase","description":"Overall Phase was defined as 0 to 24 hours following initiation of chemotherapy.\n\nNo vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Receiving MEC With No Vomiting in the Delayed Phase","description":"Overall Phase was defined as 24 to 120 hours following initiation of chemotherapy.\n\nNo vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":56},"commonTop":["Drowsiness","Abdominal distension","Headache","Abdominal distension","Dizzy"]}}}